Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 6

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 6
---
 of private assets operating in the
pharmaceutical sector. Such add-on acquisitions can expedite growth for the target and help to amplify returns for our shareholders.

●Benefit from our unique capabilities:  We
seek to acquire a business that will benefit from and capitalize on our team’s unique operating expertise, extensive industry network
and financing experience.

●Qualified management team:  We
seek to acquire a business that allows our team to partner with proven and established management teams or business owners to achieve
long-term strategic and operational excellence.

●Benefit from being a public company:  We
intend to acquire a company at the point in its lifecycle at which going public, with the support of our highly experienced management
team and access to our robust industry networks, is a natural next step and that will benefit from access to a public currency to accelerate
growth.

●Products and Services provided:  Based
on our team’s unique experience and skillset, we intend to source and evaluate companies focused on the pharmaceutical sector.

This non-exclusive list of
criteria is not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based,
to the extent relevant, on some or all of these general guidelines as well as other considerations, factors and criteria that our management
may deem relevant. In the event that we decide to enter into our initial business combination with a target business that does not meet
the above criteria and guidelines, we will disclose that the target business does not meet the above criteria in our shareholder communications
related to our initial business combination, which would be in the form of proxy solicitation or tender offer materials that we would
file with the SEC.

Our Acquisition Process

We intend to leverage our
resources and network for efficient outreach. Our effort will be focused on creating proprietary transaction opportunities. We believe
personal relationships built over time are critical not just in generating transaction opportunities, but also in consummating a business
combination.

In evaluating a prospective
target business, we expect to conduct a due diligence review which may encompass, among other things, meetings with incumbent management
and employees, document reviews, interviews of customers and suppliers, inspection of facilities, as applicable, as well as a review of
financial, operational, legal and other information which will be made available to us.

We are not prohibited from
pursuing an initial business combination with a company that is affiliated with any of our initial shareholders or members of our management
team. In the event we seek